Syringe exchange programs and harm reduction: New evidence in the wake of the opioid epidemic

[1]  J. Gardner.  Two-stage differences in differences , 2022, 2207.05943.

[2]  H. Cooper,et al.  Factors that influence enrollment in syringe services programs in rural areas: a qualitative study among program clients in Appalachian Kentucky , 2021, Harm Reduction Journal.

[3]  D. Feaster,et al.  Reduction in injection risk behaviors after implementation of a syringe services program, Miami, Florida. , 2021, Journal of substance abuse treatment.

[4]  Christopher M. Jones,et al.  The American Opioid Epidemic in Special Populations: Five Examples. , 2020, NAM perspectives.

[5]  O. Weiland,et al.  Significant decrease in injection risk behaviours among participants in a needle exchange programme , 2020, Infectious diseases.

[6]  Liyang Sun,et al.  Estimating Dynamic Treatment Effects in Event Studies With Heterogeneous Treatment Effects , 2018, Journal of Econometrics.

[7]  Pedro H. C. Sant'Anna,et al.  Difference-in-Differences with Multiple Time Periods , 2018, Journal of Econometrics.

[8]  Xavier d'Haultfoeuille,et al.  Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects , 2018, American Economic Review.

[9]  H. Mosher,et al.  Regional and Rural-Urban Variation in Opioid Prescribing in the Veterans Health Administration. , 2019, Military medicine.

[10]  Kevin Lang,et al.  The Promise and Pitfalls of Differences-in-Differences: Reflections on 16 and Pregnant and Other Applications , 2018, Journal of Business & Economic Statistics.

[11]  D. Patterson,et al.  Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5‐Year Update , 2018, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[12]  Dhaval M Dave,et al.  Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse , 2017, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].

[13]  M. Deshpande,et al.  Who is Screened Out? Application Costs and the Targeting of Disability Programs , 2017, American Economic Journal: Economic Policy.

[14]  Laura F White,et al.  Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis , 2018, American journal of public health.

[15]  Justine Mallatt.  The Effect of Prescription Drug Monitoring Programs on Opioid Prescriptions and Heroin Crime Rates , 2018 .

[16]  Andrew Goodman-Bacon.  Difference-in-Differences with Variation in Treatment Timing , 2018, Journal of Econometrics.

[17]  Jennifer L. Doleac,et al.  The Moral Hazard of Lifesaving Innovations: Naloxone Access, Opioid Abuse, and Crime , 2018, SSRN Electronic Journal.

[18]  Molly Schnell,et al.  Addressing the Opioid Epidemic: Is There a Role for Physician Education? , 2017, American Journal of Health Economics.

[19]  S. Goetz,et al.  Explaining Spatial Disparities in Drug Overdoses, 1970-2014 , 2017 .

[20]  C. Ruhm,et al.  Geographic Variation in Opioid and Heroin Involved Drug Poisoning Mortality Rates. , 2017, American journal of preventive medicine.

[21]  Randall Young,et al.  Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015 , 2017, MMWR. Morbidity and mortality weekly report.

[22]  Xavier Jaravel,et al.  Revisiting Event Study Designs , 2017 .

[23]  T. Buchmueller,et al.  The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare , 2016 .

[24]  J. Lindo,et al.  Substance Abuse Treatment Centers and Local Crime , 2016, SSRN Electronic Journal.

[25]  Jill R Horwitz,et al.  State Legal Restrictions and Prescription-Opioid Use among Disabled Adults. , 2016, The New England journal of medicine.

[26]  Harold Alan Pincus,et al.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians. , 2016, Health affairs.

[27]  S. Slavova,et al.  Drug Overdose Deaths: Let's Get Specific , 2015, Public health reports.

[28]  Isaac D. Swensen.  Substance-abuse treatment and mortality , 2015 .

[29]  C. Banta-Green,et al.  Who prescribes buprenorphine for rural patients? The impact of specialty, location and practice type in Washington State. , 2013, Journal of substance abuse treatment.

[30]  J. Solomon,et al.  Syringe exchange programs around the world : The global context , 2009 .

[31]  D. Huo,et al.  Needle Exchange and Injection-Related Risk Behaviors in Chicago: A Longitudinal Study , 2007, Journal of acquired immune deficiency syndromes.

[32]  Jeffrey S. DeSimone.  Needle exchange programs and drug infection behavior. , 2005, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].

[33]  Harold A. Pollack,et al.  Cost-effectiveness of Harm Reduction in Preventing Hepatitis C among Injection Drug Users , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  H. Pollack.  Can we protect drug users from hepatitis C? , 2001, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].

[35]  D. Vlahov,et al.  Syringe exchange not associated with social network formation: results from Baltimore , 2000, AIDS.

[36]  M. Schechter,et al.  Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. , 1999, AIDS.